Conditions: Diabetes Mellitus Type 2 Non Alcoholic Fatty Liver Disease Obesity
Keywords: diabetes mellitus type 2 non alcoholic fatty liver disease obesity amlexanox
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 7
Healthy volunteers: no

Brief summary:
This study involves the use of a research drug, Amlexanox, for the treatment of type 2 diabetes, insulin resistance, obesity and non-alcoholic fatty liver disease (NAFLD). Amlexanox is taken orally in a pill three times a day. The investigators plan to continue therapy for a period of 12 weeks followed by a follow-up 4 weeks after therapy ends. The investigators will evaluate the changes in metabolic parameters (e.g. blood cholesterol, liver function, insulin resistance) and body composition characteristics (e.g. the pattern of fat distribution in the body). Seven eligible subjects in this study will also be evaluated for a change in liver disease by a liver biopsy.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Amlexanox
Intervention descriptions: intervention 1: None

Protocol document: